| ¿µ¹® | growth hormone | ÇÑ±Û | ¼ºÀåÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ³úÇϼöü Àü¿±¿¡¼ ºÐºñµÇ´Â È£¸£¸óÁß Çϳª·Î¼ ½Ã»óÇϺÎÀÇ ¼ºÀåÈ£¸£¸ó¹æÃâ È£¸£¸ó¿¡ ÀÇÇØ ºÐºñ°¡ ÀÚ±ØµÇ¸ç ¼Ò¸¶Å佺Ÿƾ(somatostatin: ÀÌÀÚ¿¡¼ ºÐºñµÇ¸ç, ¼ºÀåÈ£¸£¸ó¿¡ ¹Ý´ëµÇ´Â ÀÛ¿ëÀ» ÇÔ)¿¡ ÀÇÇØ ºÐºñ°¡ ¾ïÁ¦µÈ´Ù. ¼ºÀå È£¸£¸ó ¹æÃâ È£¸£¸óÀº µµÆÄ¹Î(dopamine)À¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¼ºÀå È£¸£¸óÀº ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½Ã۸ç ƯÈ÷ °ñÀÇ ¼ºÀåÀ» ÀÚ±ØÇϴµ¥ ±× ÀÛ¿ëÀº Á÷Á¢ ¼¼Æ÷¿¡ ÀÛ¿ëÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó °£°ú ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ±×°÷¿¡¼ ¼Ò¸¶Åä¸ÞµòÀ» »ý¼ºÇϸç ÀÌ ¼Ò¸¶Åä¸ÞµòÀÌ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ÇÑÆí ¼ºÀå È£¸£¸óÀº ¼ºÀå¿¡ ÇÊ¿äÇÑ ´Ü¹éÁú ÇÕ¼ºÀ» Ç×Áø½ÃŰ°í ¿¡³ÊÁö´Â Áö¹æÀ» ÀÌ¿ëÇÏ¿© ¾ò°ÔÇϹǷΠÁö¹æÀÌ¿ëÈ£¸£¸óÀ̶ó°íµµ ºÒ¸°´Ù. ¼ºÀå È£¸£¸óÀÌ °ú´Ù ºÐºñµÇ¸é °ÅÀÎÁõ, ¸»´Üºñ´ëÁõÀÌ À¯¹ßµÇ¸ç ¼ºÀå È£¸£¸óÀÌ °áÇÌµÇ¸é ¼ºÀåºÎÁøÀÌ ¿Â´Ù. |
||
| ¿µ¹® | growth factor | ÇÑ±Û | ¼ºÀåÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷ÀÇ ºÐÈ ¹× ¼ºÀå¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú. ¼ºÀåÀÎÀÚ´Â Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ žÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù. |
||
| ¿µ¹® | basal metabolic rate(BMR) | ÇÑ±Û | ±âÃÊ´ë»çÀ² |
|---|---|---|---|
| ¼³¸í | Ç¥ÁØ ±âÃÊ´ë»ç·®°ú ºñ±³ÇßÀ» ¶§ °³Ã¼ ±âÃÊ´ë»ç·®ÀÌ º¸ÀÌ´Â ÆíÂ÷¸¦ Ç¥½ÃÇÏ´Â Áö¼ö. ±âÃÊ´ë»ç·®Àº »ý¸íÀ» À¯ÁöÇϴµ¥ ÇÊ¿äÇÑ ÃÖ¼ÒÇÑÀÇ ¿¡³ÊÁö ´ë»ç·®À̸ç, ¼º°ú ¿¬·ÉÀÌ µ¿ÀÏÇÑ °Ç°ÀÎÀÇ ±âÃÊ´ë»ç·®Àº üǥ¸éÀû¿¡ ºñ·ÊÇÑ´Ù. À̰ÍÀ» üǥ¸éÀûÀÇ ¹ýÄ¢À̶ó°í Çϸç, 1882³â µ¶ÀÏÀÇ ´ë»ç»ý¸®ÇÐÀÚ M. ºê·ç³Ê¿¡ ÀÇÇØ Á¦Ã¢µÇ¾ú´Ù. üǥ¸éÀûÀº ½ÅÀå°ú üÁß¿¡ ÀÇÇØ »êÃâµÈ´Ù. µû¶ó¼ ¼º-¿¬·É-½ÅÀå-üÁßÀ» ¾Ë¸é Ç¥ÁرâÃÊ·® Y°¡ »êÃâµÇ°í ½ÇÁ¦ÀÇ ±âÃÊ´ë»ç·® X´Â »ê¼Ò¼Òºñ·®°ú ÀÌ»êÈź¼Ò ¹ß»ý·®¿¡¼ »êÃâµÈ´Ù. ±×¸®°í X¿Í YÀÇ Â÷À̸¦ Y·Î ³ª´« °ª(%)À» ±âÃÊ´ë»çÀ²À̶ó°í ÇÑ´Ù. °æÇèÀûÀ¸·Î ¾òÀº BMRÀÇ °£´ÜÇÑ ÃøÁ¤¹ýµµ ÀÖÀ¸¸ç ´ÙÀ½°ú °°Àº ½ÄÀ¸·Î ±¸ÇÑ´Ù. ÀÌ ½Ä¿¡¼ ¸ÆÆøÀ̶õ ÃÖ°íÇ÷¾Ð°ú ÃÖÀúÇ÷¾ÐÀÇ Â÷¸¦ ¸»ÇÑ´Ù. BMR(%)=0.75(1ºÐ ¸Æ¹Ú¼ö + 0.74¡¿¸ÆÆø)£72. BMRÀÌ 10% À̳»À̸é Á¤»ó¹üÀ§, +10% ÀÌ»óÀÌ¸é ±âÃÊ´ë»çÇ×Áø, £10% ÀÌÇÏÀÌ¸é ±âÃÊ´ë»ç ÀúÇ϶ó°í ÇÑ´Ù. ±âÃÊ´ë»ç´Â °øº¹½Ã(½ÄÈÄ 10½Ã°£ °æ°ú)¿¡ ¾ÈÁ¤µÈ »óÅ¿¡¼ ´ÜÀ§ ½Ã°£´ç ÀÌ¿ëµÇ´Â ¿¡³ÊÁöÀÇ ¾ç, Áï, ÇÑ ½Ã°£´ç, ¸ö Ç¥¸éÀÇ 1m2´ç ¶Ç´Â ¸ö¹«°Ô 1kg ´ç Ä®·Î¸®·Î ³ªÅ¸³½´Ù. À̰ÍÀº °³Àο¡ µû¶ó ´Ù¸£¸ç Àå±â°£¿¡´Â °ÅÀÇ º¯È°¡ ¾øÁö¸¸ Áúº´ µîÀ¸·Î ÀÎÇØ º¯µ¿µÈ´Ù. ½ÇÃøÇÑ ±âÃÊ´ë»ç¸¦ Ç¥ÁØÄ¡¿Í ºñ±³ÇÔÀ¸·Î½á Áúº´ÀÇ Áø´Ü µî¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖ´Ù BMR=(½ÇÃøÄ¡-Ç¥ÁØÄ¡)/Ç¥ÁØÄ¡ ¡¿100(%)·Î ³ªÅ¸³½´Ù. |
||
| ¿µ¹® | five-year survival rate | ÇÑ±Û | ¿À³â»ýÁ¸À² |
|---|---|---|---|
| ¼³¸í | 1. µ¿ÀÏ Áúº´ÀÇ Áø´Ü ȤÀº Ä¡·á ÈÄ, 5³âÀÌ °æ°ú µÈ µÚÀÇ »ýÁ¸ÀÚ¼öÀÇ Ç¥Çö. 2. ¾ÏÀÇ Áø´Ü ¶Ç´Â Ä¡·á µÚ¿¡ °Ë»ç¸¦ ¹Ýº¹ÇÏ¿© 5³â µ¿¾È »ì¾Æ ÀÖ´Â »ç¶÷ÀÇ ¹éºÐÀ². Ä¡·á ÈÄ 5³â µ¿¾È »ýÁ¸Çϸé ÀÏ´Ü Ä¡À¯µÈ °ÍÀ¸·Î °£ÁÖÇÑ´Ù. |
||
| ¿µ¹® | ESR(Erythrocyte Sedimentation Rate) | ÇÑ±Û | ÀûÇ÷±¸Ä§°¼Óµµ, Ç÷ħ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÌ ÀÀ°íµÇ´Â °ÍÀ» ¹æÁöÇÏ´Â Ç×ÀÀ°íÁ¦¸¦ ³ÖÀº Ç÷¾×À» ħ°¿ë À¯¸®°ü¿¡ ³Ö¾î °¡¸¸È÷ ¼¼¿ö µÎ¾úÀ» ¶§ ÀûÇ÷±¸°¡ °¡¶ó¾É´Â ¼Óµµ¸¦ À̸£´Â ¸»ÀÌ´Ù. 1918³â ½º¿þµ§ÀÇ º´¸®ÇÐÀÚ ÆÄ·¹¿ì½ºÀÇ Ã¢¾È¿¡ ÀÇÇÑ °ÍÀÌ´Ù. ÃøÁ¤¹æ¹ýÀ¸·Î ¿©·¯ °¡Áö°¡ Àִµ¥, ±¹Á¦Ç¥ÁعýÀ¸·Î´Â 1973³â ¿þ½ºÅͱ׷»¹ýÀÇ 1½Ã°£¹ýÀÌ ¼±Á¤µÇ¾úÀ¸¸ç, 1977³â ±×°ÍÀ» °³Á¤ÇÏ¿© °¢±¹¿¡¼ ¾²µµ·Ï ±ÇÀåÇϰí ÀÖ´Ù. 1½Ã°£ ÈÄ Ä§°¿ë À¯¸®°ü À§ÂÊÀÇ Ç÷Àå±âµÕÀÇ ³ôÀ̸¦ mm·Î Àоî, ±×°ÍÀ» ÀûÇ÷±¸Ä§°ÀÇ 1½Ã°£°ªÀ¸·Î ÇÑ´Ù. ¸¸¾à Ç÷Àå°ú ÀûÇ÷±¸ÀÇ °æ°è°¡ ¼±¸íÇÏÁö ¸øÇÑ °æ¿ì, ÀûÇ÷±¸ÀÇ ¹Ðµµ°¡ ±× ÀÌÇÏ¿¡¼´Â ÀÏÁ¤ÇÏ´Ù°í ¿©°ÜÁö´Â °÷ÀÇ ´«±ÝÀ» Àоî ÀûÇ÷±¸Ä§°ÀÇ 1½Ã°£°ªÀ¸·Î ÇÑ´Ù. ÃøÁ¤ ¶§ÀÇ ½Ç³»¿Âµµ´Â 18~25µµ·Î ÇÑ´Ù. ÀϹÝÀûÀ¸·Î À̺¸´Ù ¿Âµµ°¡ ³ôÀº °æ¿ì´Â Ç÷ħ¹ÝÀÀÀÌ ÃËÁøµÇ¸ç, ³·Àº °æ¿ì´Â ´Ê¾îÁø´Ù. Á¤»ó °ªÀº 2~10mm(³²ÀÚ), 3~15mm(¿©ÀÚ)À̸ç 15¼¼ ÀÌÇÏÀÇ ¾î¸°ÀÌ, 50¼¼ ÀÌ»óÀÇ °í·ÉÀÚ¿¡¼´Â ¾à°£ ³ô´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| CPR | cardiopulmonary reserve; cardiopulmonary resuscitation; centripetal rub; cerebral cortex perfusion r... |
| CSR | central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie... |
| PR | by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr... |
| NBS | N-bromosuccinimide; National Bureau of Standards; neuroblastoma supressor; nevoid basal cell carcino... |
| RGR | Relative growth rate |
|---|---|
| GR | growth rate |
| HB-EGF | Heparin binding epidermal growth factor-like growth factor |
| HB-EGF | Heparin-binding epidermal growth factor (EGF)-like growth factor |
| GH-IGF-I | growth hormone-insulin-like growth factor I |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
acute angle
| growth rate | <biology, cell culture, ecology> The rate, or speed, at which the number of organisms in a population increases. This can be calculated by dividing the change in the number of organisms from one point in time to another by the amount of time in the interval between the points of time. The phrase is most often used to describe growth of cells or microorganisms in laboratory cultures and usually expressed as the generation time. (21 Jun 2000) |
|---|---|
| growth rate of population | <epidemiology> A measure of population change in the absence of migration, comprising addition of newborns and subtraction of deaths; the result is known as the natural rate of increase of the population; it is the difference between the crude birth rate and the crude death rate. (05 Mar 2000) |
| beta-normal | <radiobiology> Beta-N, the normalised beta, is beta relative to the beta limit. (09 Oct 1997) |
| big axillary nodes and normal breasts | <radiology> Consider: lymphoma, leukaemia, rheumatoid arthritis (12 Dec 1998) |
| gallium uptake with normal chest film | <radiology> Pulmonary drug toxicity, tumour infiltration, sarcoidosis, pneumocystis carinii see: lung: gallium imaging (12 Dec 1998) |
| range, normal | Normal results can fall outside the normal range. By convention, the normal range is set to cover ninety-five percent (95%) of values from a normal population. Five percent (5%) of normal results therefore fall outside the normal range. (12 Dec 1998) |
| human normal immunoglobulin | A preparation of the proteins of liquid human plasma, containing the antibodies of normal adults; it is obtained from pooled liquid human plasma from a number of donors and may be prepared by precipitation with organic solvents under controlled conditions of pH, ionic strength, and temperature. Synonym: human normal immunoglobulin. (05 Mar 2000) |
| normal | <microscopy> An imaginary line forming a right angle with the tangent to a curved surface at a particular point. It is used as a basis for determining angles of incidence, reflection, and refraction. (05 Aug 1998) |
| normal animal | In research, an experimental animal that has neither suffered an attack of a particular disease nor received an injection of a specific microorganism or its toxin. (05 Mar 2000) |
| normal antibody | Antibody demonstrable in the serum or plasma of various persons or animals not known to have been stimulated by specific antigen, either artificially or as the result of naturally occurring contact. Synonym: natural antibody. (05 Mar 2000) |
| normal antitoxin | Serum that is capable of neutralizing an equivalent quantity of a normal toxin solution. (05 Mar 2000) |
| normal bite | That arrangement of teeth and their supporting structure which is usually found in health and which approaches an ideal or standard arrangement. Synonym: normal bite. Synonym: neutral occlusion. (05 Mar 2000) |
| normal butyric acid | (also written as n-butyric acid), butanoic acid, CH3CH2CH2COOH, which occurs in combination with glycerol in cow's butter; and isobutyric acid, 2-methylpropanoic acid, (CH3)2CHCOOH, one of the intermediates in valine catabolism, found in combination with glycerol in croton oil and elsewhere. (05 Mar 2000) |
| normal cholesteraemic xanthomatosis | histiocytosis |
| normal distribution | Continuous frequency distribution of infinite range. Its properties are as follows: 1) continuous, symmetrical distribution with both tails extending to infinity; 2) arithmetic mean, mode, and median identical; and 3) shape completely determined by the mean and standard deviation. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|